Bovine Fibrinogen (Bos taurus)

Bovine fibrinogen is a blood-derived glycoprotein from Bos taurus that serves as the primary substrate for thrombin-mediated clot formation, converting into insoluble fibrin polymers to achieve hemostasis. Its clinical application centers on surgical hemostatic agents, particularly fibrinogen-collagen fleece composites used in neurosurgery and wound closure procedures.

Origin & History

Bovine fibrinogen is a plasma glycoprotein derived from the blood of Bos taurus (domestic cattle), extracted through purification processes involving precipitation and chromatography. It is a 340 kDa hexameric protein composed of three polypeptide chains (Aα, Bβ, γ) linked by disulfide bonds, primarily used in biomaterials and tissue engineering applications rather than as an oral supplement.

Historical & Cultural Context

No evidence of bovine fibrinogen in traditional medicine systems was found. It is a modern biomaterial developed for 20th-21st century scientific applications in coagulation research and tissue engineering, without historical precedents in Ayurveda, TCM, or other traditional practices.

Health Benefits

• Effective hemostasis in neurosurgical procedures when used as fibrinogen-based collagen fleece (retrospective study, n=288)
• Potential wound healing support through fibrin clot formation (preclinical evidence only)
• May interact with iron homeostasis through heme-binding properties (in-vitro studies)
• Enhanced clot mechanics in experimental models (laboratory evidence)
• Biocompatibility in surgical settings as topical biomaterial (limited clinical data)

How It Works

Bovine fibrinogen is cleaved by the serine protease thrombin at fibrinopeptide A and B sites on the Aα and Bβ chains, generating fibrin monomers that self-polymerize into a cross-linked gel stabilized by Factor XIIIa-mediated ε-(γ-glutamyl)lysine isopeptide bonds. The resulting fibrin matrix activates αvβ3 and α5β1 integrins on platelets and fibroblasts, facilitating platelet aggregation and initiating wound remodeling. Additionally, bovine fibrinogen contains heme-binding domains capable of interacting with iron-containing molecules in vitro, potentially modulating local iron homeostasis, though this pathway remains uncharacterized in vivo.

Scientific Research

Clinical evidence for bovine fibrinogen as a supplement is notably absent. One retrospective study (n=288) evaluated fibrinogen-based collagen fleece for dural sealing in neurosurgery (PMID: 11956939), but no randomized controlled trials or meta-analyses exist for supplemental use. Current research focuses primarily on preclinical wound models and biomaterial applications.

Clinical Summary

A retrospective study of 288 neurosurgical patients demonstrated effective intraoperative hemostasis using fibrinogen-based collagen fleece (TachoComb), with no major adverse hemostatic outcomes reported, though the lack of a randomized control group limits causal inference. Preclinical models suggest fibrin clot scaffolds accelerate wound re-epithelialization and fibroblast migration, but no peer-reviewed human RCTs specifically isolating bovine fibrinogen as a supplement for wound healing have been published. In-vitro data indicate heme-iron binding activity at physiological pH, yet no clinical trials have quantified effects on systemic iron parameters or hemoglobin levels in humans. Overall, the evidence base is strongest for topical surgical hemostatic use and remains preliminary or absent for oral supplementation, wound care, or iron metabolism endpoints.

Nutritional Profile

Bovine Fibrinogen (Bos taurus) is a high-molecular-weight glycoprotein (MW ~340 kDa) composed predominantly of protein (~96-98% by dry weight), with trace carbohydrate moieties (~3-4% by weight as N-linked oligosaccharide chains including sialic acid, galactose, mannose, and N-acetylglucosamine). Amino acid composition is rich in glutamic acid/glutamine (~11%), aspartic acid/asparagine (~9%), leucine (~8%), lysine (~7%), and glycine (~6%), with a full complement of essential amino acids present. Contains three disulfide-bonded polypeptide chain pairs (Aα, Bβ, Gγ). Iron-binding capacity is attributed to heme-associated porphyrin interactions rather than intrinsic iron content; trace iron may be present at <0.1 mg/g. Calcium is functionally relevant as a cofactor for Factor XIII-mediated cross-linking, present at approximately 2-4 calcium-binding sites per molecule. No dietary fiber, no lipids in purified form, and negligible carbohydrate caloric contribution. Bioavailability as a dietary protein is limited in its fibrinogen form due to large molecular size and structural complexity; proteolytic digestion yields bioavailable amino acid fragments. As a pharmaceutical/surgical hemostatic agent, systemic absorption of fibrin degradation products (FDPs) occurs post-clot lysis via plasmin activity. Zinc is present in trace amounts (<0.05 mg/g) associated with structural domains. No significant vitamin content detected in purified fibrinogen preparations.

Preparation & Dosage

No clinically studied dosage ranges exist for bovine fibrinogen as an oral supplement. In biomaterial applications, it is used topically in fixed preparations without standardized dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin K, Calcium, Vitamin C, Zinc, Collagen peptides

Safety & Interactions

Bovine fibrinogen carries a risk of hypersensitivity and anaphylactic reactions due to its xenogeneic (bovine) protein origin, and individuals with known bovine protein allergies should avoid all formulations. As a blood-derived product, theoretical risk of prion transmission (bovine spongiform encephalopathy) exists, although modern manufacturing employs viral inactivation and sourcing controls to minimize this risk. Concomitant use with anticoagulants such as heparin, warfarin, or direct oral anticoagulants (DOACs like rivaroxaban or apixaban) may counteract fibrinogen-driven clot formation, and concurrent thrombolytic agents (e.g., tissue plasminogen activator) represent a direct pharmacological antagonism. Safety in pregnancy, lactation, and pediatric populations has not been established in controlled clinical trials, and use in these groups should only occur under direct medical supervision.